CD19 is a key target in various clinical applications, particularly in the diagnosis and treatment of B cell-related diseases. It is widely used as a marker in flow cytometry and immunohistochemistry for identifying B cell malignancies, such as chronic lymphocytic leukemia (CLL) and B cell lymphomas. Furthermore, CD19 is the target of CAR-T cell therapy, an innovative treatment where patient-derived T cells are engineered to express chimeric antigen receptors that specifically target CD19 on B cells, leading to the destruction of malignant cells.
